2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧28 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·7 t sittenI allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."
I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
2 päivää sittenSome AI stuff……we have seen major new and existing institutional investors take significant positions in Egetis recently. The most concrete evidence comes from the MSEK 350 oversubscribed private placement, where elite U.S. healthcare funds and major Nordic institutional players anchored the raise at SEK 5.25 per share. Here is a breakdown of the specific institutional buyers driving recent accumulation: Key Institutional Buyers & Participants New & Anchor U.S. Biotech Specialists: * Frazier Life Sciences: Acted as the primary anchor for the capital raise. Frazier is a premier global biotech fund known for taking aggressive long positions in late-stage regulatory candidates. * Invus: A major global private equity and public healthcare fund with deep experience scaling commercial biotech launches. * Woodline Partners: A prominent long/short equity manager focused on healthcare and life sciences. * Parkman Healthcare Partners: A high-conviction U.S. institutional fund specializing exclusively in binary regulatory catalysts and commercialization. Nordic Institutional & Long-Only Funds: * Linc AB: Bengt Julander's renowned Swedish life science investment firm added to its long-term position. * AP4 (The Fourth Swedish National Pension Fund): Major state-backed institutional capital participating to capture the pre-PDUFA run-up. * Cidro AB: Established domestic long-only investor. What This Buying Tells Us 1. Smart Money Anchored lower: These specialized funds took massive positions at SEK 5.25, providing a firm institutional baseline. 2. No Post-Placement Dumping: Rather than selling off after shares were issued, the stock has rallied from 5.25 SEK to ~7.95 SEK. This confirms that institutional buyers did not flip their shares for quick gains; they are holding through the September 28 PDUFA date. 3. Low Dilution Impact: The directed share issue was heavily oversubscribed, proving that demand for shares from new international institutional buyers far exceeded the supply available in the market. Institutional involvement entering the final 30 days is exceptionally strong, backed by dedicated U.S. healthcare specialists who rarely take large positions unless their internal risk models predict a >90% probability of success.
·3 päivää sittenEgetis can easily be valued around 15-16kr after pdufa. Doubling in the short term.
I don't think there will be a big sell the news when we hopefully get approved in US. All models I could find seem to suggest that an approval from FDA justifies approx. a doubling in stock price from here...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenI allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
- 2 päivää sittenSome AI stuff……we have seen major new and existing institutional investors take significant positions in Egetis recently. The most concrete evidence comes from the MSEK 350 oversubscribed private placement, where elite U.S. healthcare funds and major Nordic institutional players anchored the raise at SEK 5.25 per share. Here is a breakdown of the specific institutional buyers driving recent accumulation: Key Institutional Buyers & Participants New & Anchor U.S. Biotech Specialists: * Frazier Life Sciences: Acted as the primary anchor for the capital raise. Frazier is a premier global biotech fund known for taking aggressive long positions in late-stage regulatory candidates. * Invus: A major global private equity and public healthcare fund with deep experience scaling commercial biotech launches. * Woodline Partners: A prominent long/short equity manager focused on healthcare and life sciences. * Parkman Healthcare Partners: A high-conviction U.S. institutional fund specializing exclusively in binary regulatory catalysts and commercialization. Nordic Institutional & Long-Only Funds: * Linc AB: Bengt Julander's renowned Swedish life science investment firm added to its long-term position. * AP4 (The Fourth Swedish National Pension Fund): Major state-backed institutional capital participating to capture the pre-PDUFA run-up. * Cidro AB: Established domestic long-only investor. What This Buying Tells Us 1. Smart Money Anchored lower: These specialized funds took massive positions at SEK 5.25, providing a firm institutional baseline. 2. No Post-Placement Dumping: Rather than selling off after shares were issued, the stock has rallied from 5.25 SEK to ~7.95 SEK. This confirms that institutional buyers did not flip their shares for quick gains; they are holding through the September 28 PDUFA date. 3. Low Dilution Impact: The directed share issue was heavily oversubscribed, proving that demand for shares from new international institutional buyers far exceeded the supply available in the market. Institutional involvement entering the final 30 days is exceptionally strong, backed by dedicated U.S. healthcare specialists who rarely take large positions unless their internal risk models predict a >90% probability of success.
- ·3 päivää sittenEgetis can easily be valued around 15-16kr after pdufa. Doubling in the short term.I don't think there will be a big sell the news when we hopefully get approved in US. All models I could find seem to suggest that an approval from FDA justifies approx. a doubling in stock price from here...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
2026 Q2 -tulosraportti
UUTTA
7 päivää sitten
‧28 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 6.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 21.8. | ||
2026 Q1 -tulosraportti 29.4. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 25.11.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·7 t sittenI allow myself to repeat this post so that any new shareholders are not scared by Nordnet and Pareto not correcting a totally erroneous price target: Here is the story of the erroneous price target of 1.6, which is still displayed on Nordnet's page: The low share price is probably due to continued after-effects of Pareto's catastrophic erroneous analysis at the end of November, where the analyst believed that there were already other products on the market that Egetis would have to compete with and lowered the price target to 1.60. A couple of days later, a price target came from Redeye, which was apparently around 13. Pareto's erroneous analytical basis, which many others fortunately objected to - but which Pareto has not corrected and acted upon - and which Nordnet unfortunately continues to propagate as "lowest price target" instead of removing it when it was demonstrably based on an error - or asking Pareto to retract their erroneous analysis. Incidentally, the situation was so abnormal - that rarely seen reactions were highly appropriate. I have never seen another analysis firm directly attack Pareto and their analytical basis, as we fortunately saw some do in November. It was highly necessary and commendably quick - and completely unprecedented. If you have forgotten the matter, look at the posts below at the end of November. Here is an excerpt from Stiefel's correction, which shows Pareto's misconception - but see more below in November. "Pareto lowered its recommendation for the stock on Wednesday to sell from hold with a target price reduction to 1:60 kronor from a previous 6 kronor. In (the erroneous) analysis, Pareto wrote that an American price for Emcitate of 0.1 million dollars per year seems extremely high without any proven neurocognitive effect. Especially considering that there is a much cheaper alternative treatment (PTU+LT4) for thyrotoxicosis, a condition with an increased amount of thyroid hormone in the blood regardless of cause."I was wrong about this, the answer from Nordnet: Thank you for your message. That's a good question. Nordnet takes no position whatsoever regarding target prices and assumptions. Analysts make assumptions about factors such as demand, growth, and competition to estimate what a stock might be worth and what its price might be in the future, in this case 12 months from publication. Target prices are based on the circumstances at the time of publication. Please note that target prices can be up to 90 days old. If an analyst has published several target prices in the last 90 days, the newest one is included in the data. Make sure to make your own assessment and do not rely solely on analysts' assessments. If you have questions regarding target prices, you should contact the institution that monitors and sets them directly. It is therefore not Nordnet's analysts who set target prices. We do not engage in investment advice and remain completely impartial regarding the development of specific securities. I wish you a nice day.
- 2 päivää sittenSome AI stuff……we have seen major new and existing institutional investors take significant positions in Egetis recently. The most concrete evidence comes from the MSEK 350 oversubscribed private placement, where elite U.S. healthcare funds and major Nordic institutional players anchored the raise at SEK 5.25 per share. Here is a breakdown of the specific institutional buyers driving recent accumulation: Key Institutional Buyers & Participants New & Anchor U.S. Biotech Specialists: * Frazier Life Sciences: Acted as the primary anchor for the capital raise. Frazier is a premier global biotech fund known for taking aggressive long positions in late-stage regulatory candidates. * Invus: A major global private equity and public healthcare fund with deep experience scaling commercial biotech launches. * Woodline Partners: A prominent long/short equity manager focused on healthcare and life sciences. * Parkman Healthcare Partners: A high-conviction U.S. institutional fund specializing exclusively in binary regulatory catalysts and commercialization. Nordic Institutional & Long-Only Funds: * Linc AB: Bengt Julander's renowned Swedish life science investment firm added to its long-term position. * AP4 (The Fourth Swedish National Pension Fund): Major state-backed institutional capital participating to capture the pre-PDUFA run-up. * Cidro AB: Established domestic long-only investor. What This Buying Tells Us 1. Smart Money Anchored lower: These specialized funds took massive positions at SEK 5.25, providing a firm institutional baseline. 2. No Post-Placement Dumping: Rather than selling off after shares were issued, the stock has rallied from 5.25 SEK to ~7.95 SEK. This confirms that institutional buyers did not flip their shares for quick gains; they are holding through the September 28 PDUFA date. 3. Low Dilution Impact: The directed share issue was heavily oversubscribed, proving that demand for shares from new international institutional buyers far exceeded the supply available in the market. Institutional involvement entering the final 30 days is exceptionally strong, backed by dedicated U.S. healthcare specialists who rarely take large positions unless their internal risk models predict a >90% probability of success.
- ·3 päivää sittenEgetis can easily be valued around 15-16kr after pdufa. Doubling in the short term.I don't think there will be a big sell the news when we hopefully get approved in US. All models I could find seem to suggest that an approval from FDA justifies approx. a doubling in stock price from here...
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt